HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 357 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $930,018 | +21.2% | 17,762 | -5.8% | 0.01% | +25.0% |
Q1 2024 | $767,347 | +10.8% | 18,863 | +0.7% | 0.01% | 0.0% |
Q4 2023 | $692,335 | -4.0% | 18,732 | -0.8% | 0.01% | -20.0% |
Q3 2023 | $721,407 | +3.1% | 18,885 | -2.6% | 0.01% | +11.1% |
Q2 2023 | $699,433 | -12.6% | 19,391 | -7.5% | 0.01% | -25.0% |
Q1 2023 | $800,424 | -32.6% | 20,959 | +0.4% | 0.01% | -36.8% |
Q4 2022 | $1,187,389 | +40.7% | 20,868 | -2.3% | 0.02% | +18.8% |
Q3 2022 | $844,000 | -9.8% | 21,352 | +0.3% | 0.02% | -15.8% |
Q2 2022 | $936,000 | +14.0% | 21,284 | +3.4% | 0.02% | +35.7% |
Q1 2022 | $821,000 | -1.0% | 20,593 | -0.1% | 0.01% | +7.7% |
Q4 2021 | $829,000 | -4.1% | 20,607 | -3.0% | 0.01% | -18.8% |
Q3 2021 | $864,000 | -11.4% | 21,239 | -1.1% | 0.02% | -11.1% |
Q2 2021 | $975,000 | +67.2% | 21,477 | +53.7% | 0.02% | +50.0% |
Q1 2021 | $583,000 | -19.9% | 13,975 | -18.0% | 0.01% | -25.0% |
Q4 2020 | $728,000 | – | 17,040 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 14,092,771 | $206,177,000 | 28.12% |
BB BIOTECH AG | 8,322,860 | $121,763,000 | 3.90% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 398,633 | $4,579,000 | 2.84% |
DOHENY ASSET MANAGEMENT /CA | 227,193 | $3,324,000 | 2.43% |
SNYDER CAPITAL MANAGEMENT L P | 2,833,759 | $41,458,000 | 2.24% |
First Light Asset Management, LLC | 938,399 | $13,729,000 | 2.19% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,027,164 | $132,067,000 | 1.77% |
Taylor Wealth Management Partners | 204,277 | $2,989,000 | 1.72% |
Sterling Global Strategies LLC | 22,000 | $321,860,000 | 1.63% |
Granite Investment Partners, LLC | 988,939 | $14,468,000 | 1.06% |